Sponsors (2)
The bill aims to restore competition and reduce conflicts of interest in health care by forcing separations and strengthening enforcement, trading off the potential for lower prices and more consumer choice against risks of higher short-term costs, disrupted care continuity, lost integration efficiencies, and greater legal and regulatory uncertainty.
Patients (including low-income, Medicaid and Medicare beneficiaries) could face lower prices and fewer conflicts of interest because vertically integrated insurers/PBMs/wholesalers and health conglomerates would be required to separate, improving affordability and access to medicines and care.
Federal and state enforcers (FTC, DOJ, state AGs) would have stronger authority and faster remedies to deter anti‑competitive mergers and conduct, increasing oversight of insurance, drug-supply, and provider markets.
Patients could receive more objective care decisions and greater freedom of choice (less steering to owned facilities and fewer restrictive formularies) as ownership separations reduce conflicts of interest.
Patients, taxpayers, and insurers could face higher prices or premiums if divestiture mandates and transaction costs for forced breakups are passed through to consumers.
Patients (particularly those with chronic conditions and seniors) risk disrupted continuity of care if rapid structural separations or trustee-led sales break existing provider networks or trigger contract renegotiations and closures.
Health systems that lose integrated services may forfeit coordination efficiencies and integrated clinical programs, potentially raising operational costs, reducing some services, or harming care coordination.
Based on analysis of 3 sections of legislative text.
Bars single companies from owning both provider/management firms and insurers/PBMs or wholesalers, forces divestiture within one year, and establishes enforcement and civil remedies.
Introduced February 10, 2026 by Elizabeth Warren · Last progress February 10, 2026
Makes it unlawful for a single company to simultaneously own health-care providers/management companies and major insurance or pharmacy benefit functions, or to own providers/management companies and drug or device wholesalers. Companies in violation must divest the conflicting businesses within one year; the FTC and DOJ Antitrust Division share enforcement, must issue divestiture guidance within 30 days, and have tools including escrow penalties, trustee sales, and civil remedies (including treble damages and injunctive relief). The law also lays out findings about large vertical health-care conglomerates and their market power.